Skip to main content
Daniel H. Pink on Muck Rack

Daniel H. Pink

Washington, D.C.
As seen in: Apple Podcasts, LinkedIn, LinkedIn News, Next Big Idea Club Podcast, CNN, Medium, The New York Times, Business Insider, Forbes, Nature and
#1 New York Times Bestselling author of 7 books.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Daniel H.

Contact Daniel H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Author Correction: First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort IKF-AIO-MOONLIGHT trial

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Udo Lindig, Gunnar Folprecht, Gunter Schuch, Michael Bitzer, Volker Heinemann, Stefan Angermeier, Claus Bolling, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran
| Nature Verified
Correction to: Nature Communications https://doi.org/10.1038/s41467-026-69622-7, published online 27 February 2026 In the version of this article initially published, funding information did not acknowledge the sponsor of the trial is the Frankfurt Institute of Clinical Cancer Research IKF GmbH and that financial support and drug supply for the conduct of the trial was granted by Bristol-Myers Squibb GmbH & Co. KGaA, while the title was incomplete and did not reference the Institut für...
Open in Who Shared Issue with article?

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial | Nature Communications

|
By Sylvie Lorenzen, Thorsten Oliver Goetze, Peter C Thuss-Patience, Jorge Riera-Knorrenschild, Eray Goekkurt, Tobias Dechow, Thomas Ettrich, Ralf Dieter Hofheinz, Kim Barbara Luley, Daniel H. Pink, Gunnar Folprecht, Michael Bitzer, Volker Heinemann, Maria Loose, Sabine Junge, Claudia Pauligk, Salah-Eddin Al-Batran, Udo Lindig, Gunter Schuch, Stefan Angermeier, Claus Bolling
| Nature Verified
Abstract This multi-cohort study evaluates whether dual immune checkpoint inhibition with nivolumab and ipilimumab in parallel or sequentially, or triplet chemotherapy with nivolumab can enhance efficacy as first-line therapy for advanced or metastatic gastroesophageal adenocarcinoma. Patients are randomized 1:1 to Arm A (mFOLFOX + nivolumab 240 mg every two weeks + ipilimumab 1 mg/kg every six weeks in parallel or Arm B (mFOLFOX).
Open in Who Shared Issue with article?

Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacy | Scientific Reports

|
By Kathrin Hessling, Caroline A Brand, Christian Schwöppe, Mirjam Gerwing, Stefanie Pavelka, Andrew F. Berdel, Heike Hintelmann, Rainer Hamacher, Carsten Müller-Tidow, Gerlinde Egerer, Wolfgang Hartmann, Inga Grünewald, Lars H Lindner, Dorit Di Gioia, Judith Hecker, Sabine Maurer, Daniel H. Pink, Marius Fried, Sergio Bonilla, Anne-Marie Scheuble, Florian Lordick, Philipp Ivanyi, Manfred Fobker, Georg Lenz, Torsten Kessler, Wolfgang E Berdel, Christoph Schliemann
| Nature Verified
Abstract Trabectedin is standard for r/r soft tissue sarcomas. tTF-NGR accumulates in tumor vasculature leading to tumor vascular occlusion and tumor infarction. Both compounds in sequence could trap trabectedin inside tumors and increase its efficacy, which then optimizes the pro-coagulatory activity of tTF-NGR. This report summarizes translational data and results of the safety run-in patient cohort of the TRABTRAP trial combining trabectedin plus tTF-NGR.
Open in Who Shared Issue with article?
See all 241 licensed articles (260 Total)